These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9806175)

  • 1. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma.
    Kugler A; Seseke F; Thelen P; Kallerhoff M; Müller GA; Stuhler G; Müller C; Ringert RH
    Br J Urol; 1998 Oct; 82(4):487-93. PubMed ID: 9806175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
    J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
    Dillman R; Barth N; Vandermolen L; Mahdavi K; Beutel L; de Leon C; DePriest C; Nayak S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.
    Jocham D; Richter A; Hoffmann L; Iwig K; Fahlenkamp D; Zakrzewski G; Schmitt E; Dannenberg T; Lehmacher W; von Wietersheim J; Doehn C
    Lancet; 2004 Feb; 363(9409):594-9. PubMed ID: 14987883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.
    Jonasch E; Wood C; Tamboli P; Pagliaro LC; Tu SM; Kim J; Srivastava P; Perez C; Isakov L; Tannir N
    Br J Cancer; 2008 Apr; 98(8):1336-41. PubMed ID: 18362942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific antitumour vaccine for renal cancer.
    Fishman M; Antonia S
    Lancet; 2004 Feb; 363(9409):583-4. PubMed ID: 14987879
    [No Abstract]   [Full Text] [Related]  

  • 10. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
    Koster BD; Santegoets SJAM; Harting J; Baars A; van Ham SM; Scheper RJ; Hooijberg E; de Gruijl TD; van den Eertwegh AJM
    Cancer Immunol Immunother; 2019 Jun; 68(6):1025-1035. PubMed ID: 30852622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
    Dillman RO; Beutel LD; Cornforth AN; Nayak SK
    Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TroVax(®) vaccine therapy for renal cell carcinoma.
    Zhang RT; Bines SD; Ruby C; Kaufman HL
    Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
    Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
    Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination strategies in patients with renal cell carcinoma.
    Asemissen AM; Brossart P
    Cancer Immunol Immunother; 2009 Jul; 58(7):1169-74. PubMed ID: 19360405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor cell vaccination for treatment of renal cell carcinoma].
    Kriegmair M; Oberneder R
    Urologe A; 1995 May; 34(3):204-7. PubMed ID: 7610513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
    Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
    Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New trends in the diagnosis and treatment of renal cell carcinoma].
    Zisman A
    Harefuah; 2002 Aug; 141(8):713-7, 761. PubMed ID: 12222136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.